Ghent, Belgium
October 29, 2008
Devgen NV (Euronext
Brussels: DEVG) announced today that it has received
transparency declarations from several major shareholders
pursuant to the new transparency legislation (Belgian Act of May
2, 2007) concerning major holdings in issuers whose shares are
admitted to trading on a regulated Belgian market.
On September 1, 2008, Devgen NV had 17, 881, 500
shares outstanding. The following shareholders have informed
Devgen NV of their holdings as of September 1, 2008:
|
Shareholder |
Number
of shares |
%
of outstanding shares |
|
O.G.B.B. A. van Herk B.V. |
2,277,266 |
12.74% |
|
Petercam |
1,423,430 |
7.96% |
|
Global Opportunities Capital Asset |
1,321,730 |
7.39% |
|
Monsanto Company |
1,045,400 |
5.85% |
|
Hermes |
833,000 |
4.66% |
|
KBC Asset Management |
558,863 |
3.13% |
The above parties made their declarations
separately and are acting independently.
Information concerning the transparency
legislation
Detailed information concerning the transparency
legislation can be found in the Extract from the "Guide to
the Transparency Legislation CBFA_2008_16 of 8 July 2008"
which is available from the website of the Banking, Finance and
Insurance Commission (CBFA):
www.cbfa.be/eng/gv/ah/circ/pdf/cbfa_2008_16.pdf
For submitting the notifications the CBFA
recommends the use of its standard form TR-1 BE, which is also
available from the CBFA website:
www.cbfa.be/eng/gv/ah/circ/pdf/TR-1BE.xls
The notifications should be transmitted to both
Devgen and the CBFA. The CBFA recommends transmitting the
notifications first electronically, to the e-mail address
trp.fin@cbfa.be, and subsequently - for reasons of legal
certainty - by fax to number + 32 2 220 59 12.
It is recommended to transmit notifications to
Devgen NV by email to the attention of:
Wim Goemaere, CFO
E-mail address:
ir@Devgen.com
Fax: +32 9 324
24 25
Devgen is a public agricultural biotech and seed
company focused on developing and commercializing:
-
biotech traits and hybrid seeds to meet the
growing needs for high yielding, high quality hybrid rice,
sorghum, millet and sunflower of the Indian and other
south-east Asian markets;
-
a novel generation of biotech products to
protect a wide spectrum of crops incurred from pests; to
render crops more tolerant against stress factors such as
drought and salty soils and to decrease the need for
fertilizer use by optimizing nitrogen uptake;
-
a new generation of agrochemical products to
protect crops from damage inflicted by plant parasitic
nematodes.
Incorporated in 1997, Devgen has offices in Ghent
(Belgium), Singapore, Hyderabad (India) and Delaware (US) and
employs more than 200 people worldwide. Devgen is listed on
Euronext Brussels (ticker: DEVG) since June 2005. |
|
